CEO lowers price of AIDS drug after public backlash

The CEO of Turing Pharmaceuticals faced criticism worldwide after he hiked the price of a treatment for AIDS and cancer patients. The CEO of the company raised the price from $13.50 a tablet to $750 per tablet, close to a 5000% increase.

The drug Daraprim treats toxoplasmosis, a parasite that causes illness in those with weakened immune systems.
 
CEO Martin Shkreli justified the hike saying that the overall impact would be a minor one, and there are only 12,000 prescriptions for the drug a year. Shrekli added that proceeds will go toward developing a newer treatment with fewer side effects.

Turing Pharmaceuticals on Tuesday afternoon announced they would lower the cost of the life-saving drug. The new price was not released but he Shkreli stated the determination would be made in the next few weeks.

Shkreli said the reduction in price was a reaction to the outrage over the increase. 
 
Daraprim has been produced for over 62 years, and Turing Pharmaceuticals bought the rights to the drug last month from Impax Laboratories for $55 Million. 
 
Up Next:


Up Next

  • CEO lowers price of AIDS drug after public backlash
  • Study: Marijuana not linked to rise in auto fatalities
  • Woman clings to moving car in Virginia Beach
  • Baby deer takes some dips in family's pool
  • Police weigh manslaughter charges in London fire
  • Calvert County sheriff's deputy plays basketball with young boy
  • U.S. releases dramatic photos of Russian jet intercept
  • Johnny Depp: 'maybe it's time' to assassinate a president
  • Chaos at State Fair Meadowlands as gunshots ring out
  • Mystery surrounds 'melted mailbox' in Mesa